Head to Head Comparison: Movano (NASDAQ:MOVE) vs. iRhythm Technologies (NASDAQ:IRTC)

Movano (NASDAQ:MOVE) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Movano and iRhythm Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Movano	1	0	0	0	1.00
iRhythm Technologies	1	1	11	2	2.93

iRhythm Technologies has a consensus price target of $191.85, indicating a potential upside of 68.52%. Given iRhythm Technologies’ stronger consensus rating and higher possible upside, analysts clearly believe iRhythm Technologies is more favorable than Movano.

Risk and Volatility

Movano has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Profitability

This table compares Movano and iRhythm Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Movano	-4,231.41%	-647.91%	-298.12%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

Institutional and Insider Ownership

16.6% of Movano shares are owned by institutional investors. 10.4% of Movano shares are owned by insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Movano and iRhythm Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Movano	$430,000.00	58.34	-$18.28 million	($10.61)	-2.09
iRhythm Technologies	$747.14 million	5.01	-$44.55 million	($0.86)	-132.37

Movano has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Movano, indicating that it is currently the more affordable of the two stocks.

Summary

iRhythm Technologies beats Movano on 10 of the 15 factors compared between the two stocks.

About Movano

Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.

About iRhythm Technologies

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.